Sandoz links with Cinpharm for generics in Sub-Saharan Africa

Sandoz, the generics business of Swiss drug major Novartis (NOVN: VX), said yesterday that its German affiliate, 1A Pharma, has signed an important partnership agreement with Cinpharm, a Cameroon-owned and operated generic drug manufacturing company for the production of high-quality medicines for the Sub-Saharan African region.

The partnership will allow 1A Pharma to share technical expertise and materials to support Cinpharm to increase local production of high-quality generic medicines in the country. During the initial phase of the partnership and with the technical support of 1A Pharma, Cinpharm will undertake activities to ensure full compliance with current Good Manufacturing Practice (cGMP) standards. Sandoz will also supply Cinpharm with raw materials, including bulk active 0ingredient and packaging materials, to be used in local production.

Nick Haggar, Sandoz head of Western Europe, Middle East and Africa, commented: "With this agreement, we will be able to further increase our ongoing commitment to Sub-Saharan Africa and pave the way for local production of high-quality, affordable medicines."